BELGRADE – Montana bio-tech Bacterin International Holdings, Inc., a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, has engaged Hayden IR, a 15-year-old, highly recognized, national investor relations firm, to develop and implement a strategic investor relations program and raise its visibility and strengthen its relationships with the investment community.

 

"Over the last eight quarters, Bacterin has delivered record revenue by manufacturing and marketing superior bone graft material, biological scaffolds and related medical devices while developing bioactive anti-microbial coatings for implantable devices," commented Guy Cook, CEO of Bacterin. "We expect our outstanding growth to continue, compounded and complemented by key drivers, including our expanded direct sales force, increased product lines, accelerated use among surgeons, augmented geographic footprint which adds international markets, broadened core technology that we are leveraging into additional revolutionary products, scientific peer reviewed studies to be published and fortified strategic relationships and distribution partnerships. Accordingly, we believe it is an ideal time to retain a national investor relations firm to help us target an expanding investor audience and ensure we are communicating effectively with current and potential shareholders. We look forward to working with the team of professionals at Hayden IR to execute this important goal."

 

With offices in New York, Phoenix, Minneapolis and San Diego, Hayden IR provides a comprehensive range of investor relations services to a growing list of clients. For more than a decade, Hayden IR has been a recognized leader in driving market recognition and creating sustainable competitive advantages for more than 200 micro- and small-cap companies. Hayden delivers expertise and professionalism in such areas as investor management, relationship building, awareness campaigns, online presence and corporate identity.

 

James Carbonara, Regional VP, in Hayden IR's New York City office, added, "Bacterin represents a compelling opportunity, doubling revenue the last two years to a guided $30 - $32 million for 2011. Management expects continued rapid growth for 2012, with guidance of $53 - $56 million and generating almost 75-80% gross margins. Analysts are projecting operating margin expansion 'to the mid-20% range, if not higher', leveraging its sales force and establishing infrastructure to support $120 million to $175 million in revenue. Bacterin's broad product portfolio addresses a $7 billion market with key drivers in place to continue to capture market share as well as a possible 'call option' opportunity with OsteoSponge SC. Hayden IR believes that it is a great time for investors to be looking at Bacterin as it trades at 2.2 times the low-end of 2012 revenue guidance, lower than comparable companies in the field, in spite of a more robust growth outlook. The team at Hayden IR looks forward to articulating this opportunity to the professional investment community."

 

-Bacterin